Eye Patch Therapy for Central Serous Retinopathy (CSR)

Phase 1CompletedNCT02036632

Washington University School of Medicine12 enrolled

Overview

First, this study will investigate the viability of 24-hour eye patching as a potential treatment modality for CSR. Second, this study will assess a potential physiologic explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will aid in ameliorating disease severity and disease duration.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Central Serous Retinopathy (CSR)

Interventions

Eye PatchingDEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults 18 years of age and older * Both males and females * Patients diagnosed with active central serous retinopathy * Patients who are willing to use an eye patch in the affected eye for 24 hours * Patients who are able to make the follow up appointments as required by the study Exclusion Criteria: * Individuals under 18 years of age * Patients with vision less than 20/40 in the unaffected eye. * Patients who are not able to undergo mfERG testing in a realiable manner.

Locations (1)

Washington Universtiy School of Medicine

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Change in multi-focal ERG response and macular thickness after 24-hour patch therapy in patients with CSR

This study is a prospective control trial that will compare 24-hour eye patch therapy with the current standard of care in patients with central serous retinopathy (CSR).

Time frame: 24 hours

Change in multi-focal ERG response

Time frame: 24 hours

Secondary Outcomes

macular thickness

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.